TITLE

Long-Term Treatment of Thalidomide Ameliorates Amyloid-Like Pathology through Inhibition of β-Secretase in a Mouse Model of Alzheimer’s Disease

AUTHOR(S)
He, Ping; Cheng, Xin; Staufenbiel, Matthias; Li, Rena; Shen, Yong
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Thalidomide is a tumor necrosis factor alpha (TNFα) inhibitor which has been found to have abilities against tumor growth, angiogenesis and inflammation. Recently, it has been applied in clinic for the treatment of multiple myeloma as well as some inflammatory diseases. However, whether thalidomide has any therapeutic effects on neurodegenerative disorders, i.e. Alzheimer’s disease (AD) is not clear. AD is characterized by excessive amount of amyloid β peptides (Aβ), which results in a significant release of inflammatory factors, including TNFα in the brain. Studies have shown that inhibition of TNFα reduces amyloid-associated pathology, prevents neuron loss and improves cognition. Our recent report showed that genetic inhibition of TNFα/TNF receptor signal transduction down-regulates β amyloid cleavage enzyme 1 (BACE1) activity, reduces Aβ generation and improves learning and memory deficits. However, the mechanism of thalidomide involving in the mitigation of AD neuropathological features remains unclear. Here, we chronically administrated thalidomide on human APPswedish mutation transgenic (APP23) mice from 9 months old (an onset of Aβ deposits and early stage of AD-like changes) to 12 months old. We found that, in addition of dramatic decrease in the activation of both astrocytes and microglia, thalidomide significantly reduces Aβ load and plaque formation. Furthermore, we found a significant decrease in BACE1 level and activity with long-term thalidomide application. Interestingly, these findings cannot be observed in the brains of 12-month-old APP23 mice with short-term treatment of thalidomide (3 days). These results suggest that chronic thalidomide administration is an alternative approach for AD prevention and therapeutics.
ACCESSION #
87623594

 

Related Articles

  • Inhibition of γ-secretase worsens memory deficits in a genetically congruous mouse model of Danish dementia.  // Molecular Neurodegeneration;2012, Vol. 7 Issue 1, p19 

    The article presents a study on the effect of gamma-secretase inhibition in the memory deficits in genetically congrous mouse model of Danish dementia. It shows that the treatment of gamma-secretase inhibitor (GSI) leads to the worsening of memory deficits of familial Danish dementia (FDD) mice....

  • Increases in the Risk of Cognitive Impairment and Alterations of Cerebral β-amyloid Metabolism in Mouse Model of Heart Failure Hong, Xiaoqi; Bu, Liping; Wang, Yi; Xu, Jing; Wu, Jian; Huang, Yufang; Liu, Jie; Suo, Haiyun; Yang, Lumeng; Shi, Yuncen; Lou, Yi; Sun, Zhengliang; Zhu, Guoqi; Behnisch, Thomas; Yu, Mei; Jia, Jianguo; Hai, Wangxi; Meng, Hongping; Liang, Sheng; Huang, Fang // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Epidemiological and clinico-pathological studies indicate a causal relationship between heart disease and Alzheimer’s disease (AD). To learn whether heart disease causes an onset of AD, mice with myocardial infarction (MI) and congestive heart failure (HF) were used to test...

  • Pharmacological targeting of the β-amyloid precursor protein intracellular domain. Branca, Caterina; Sarnico, Ilenia; Ruotolo, Roberta; Lanzillotta, Annamaria; Viscomi, Arturo Roberto; Benarese, Marina; Porrini, Vanessa; Lorenzini, Luca; Calzà, Laura; Imbimbo, Bruno Pietro; Ottonello, Simone; Pizzi, Marina // Scientific Reports;4/11/2014, p1 

    Amyloid precursor protein (APP) intracellular domain (AICD) is a product of APP processing with transcriptional modulation activity, whose overexpression causes various Alzheimer's disease (AD)-related dysfunctions. Here we report that...

  • The mechanism of ?-Secretase dysfunction in familial Alzheimer disease. Chávez-Gutiérrez, Lucía; Bammens, Leen; Benilova, Iryna; Vandersteen, Annelies; Benurwar, Manasi; Borgers, Marianne; Lismont, Sam; Zhou, Lujia; Van Cleynenbreugel, Simon; Esselmann, Hermann; Wiltfang, Jens; Serneels, Lutgarde; Karran, Eric; Gijsen, Harrie; Schymkowitz, Joost; Rousseau, Frederic; Broersen, Kerensa; De Strooper, Bart // EMBO Journal;5/16/2012, Vol. 31 Issue 10, p2261 

    The mechanisms by which mutations in the presenilins (PSEN) or the amyloid precursor protein (APP) genes cause familial Alzheimer disease (FAD) are controversial. FAD mutations increase the release of amyloid ? (A?)42 relative to A?40 by an unknown, possibly gain-of-toxic-function, mechanism....

  • β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. Willemijn Menting, Kelly; Claassen, Jurgen A. H. R. // Frontiers in Aging Neuroscience;Jul2014, Vol. 6, p1 

    Alzheimer's disease (AD) and vascular dementia are responsible for up to 90% of dementia cases. According to the World Health Organization (WHO), a staggering number of 35.6 million people are currently diagnosed with dementia. Blocking disease progression or preventing AD altogether is...

  • Part-Time a-Secretases: The Functional Biology of ADAM 9, 10 and 17. Deuss, Miriam; Reiss, Karina; Hartmann, Dieter // Current Alzheimer Research;Apr2008, Vol. 5 Issue 2, p187 

    Disintegrin metalloproteases of the ADAM family form a large (at present > 40 members in mammals) family of multidomain membrane proteins that in their ectodomain combine a cystein-rich, disintegrin and a zinc metalloprotease domain. Via their metalloprotease domain, ADAMs are often implicated...

  • Consumption of Grape Seed Extract Prevents Amyloid-β Deposition and Attenuates Inflammation in Brain of an Alzheimer's Disease Mouse. YAN-JIANG WANG; THOMAS, PHILIP; JIN-HUA ZHONG; FANG-FANG BI; KOSARAJU, SHANTHA; POLLARD, ANTHONY; FENECH, MICHAEL; XIN-FU ZHOU // Neurotoxicity Research;2009, Vol. 15 Issue 1, Special section p1 

    Polyphenols extracted from grape seeds are able to inhibit amyloid-β(Aβ aggregation, reduce Aβ production and protect against Aβ neurotoxicity in vitro. We aimed to investigate the therapeutic effects of a polyphenol-rich grape seed extract (GSE) in Alzheimer's disease mice. APPSwe/...

  • Pharmacokinetics of [F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Snellman, Anniina; Rokka, Johanna; Lopez-Picon, Francisco; Eskola, Olli; Wilson, Ian; Farrar, Gill; Scheinin, Mika; Solin, Olof; Rinne, Juha; Haaparanta-Solin, Merja // European Journal of Nuclear Medicine & Molecular Imaging;Nov2012, Vol. 39 Issue 11, p1784 

    Purpose: The aim of this study was to investigate the potential of [F]flutemetamol as a preclinical PET tracer for imaging β-amyloid (Aβ) deposition by comparing its pharmacokinetics to those of [C]Pittsburgh compound B ([C]PIB) in wild-type Sprague Dawley rats and C57Bl/6N mice. In...

  • Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice. Santuccione, A C; Merlini, M; Shetty, A; Tackenberg, C; Bali, J; Ferretti, M T; McAfoose, J; Kulic, L; Bernreuther, C; Welt, T; Grimm, J; Glatzel, M; Rajendran, L; Hock, C; Nitsch, R M // Molecular Psychiatry;Mar2013, Vol. 18 Issue 3, p358 

    Serum antibodies against amyloid-β peptide (Aβ) in humans with or without diagnosis of Alzheimer's disease (AD) indicate the possibility of immune responses against brain antigens. In an unbiased screening for antibodies directed against brain proteins, we found in AD patients high serum...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics